These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9712824)

  • 1. Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model.
    Hartman AB; Venkatesan MM
    Infect Immun; 1998 Sep; 66(9):4572-6. PubMed ID: 9712824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine.
    Venkatesan MM; Hartman AB; Newland JW; Ivanova VS; Hale TL; McDonough M; Butterton J
    Infect Immun; 2002 Jun; 70(6):2950-8. PubMed ID: 12010984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity.
    Barnoy S; Jeong KI; Helm RF; Suvarnapunya AE; Ranallo RT; Tzipori S; Venkatesan MM
    Vaccine; 2010 Feb; 28(6):1642-54. PubMed ID: 19932216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Construction of prophylactic recombinant HPV58-attenuated Shigella vector live vaccine and evaluation of its protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model].
    Li WS; Liu HL; Zhang YT; Yang XF; Wang YL; Si LS
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Dec; 23(12):1163-6. PubMed ID: 18062891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model.
    Barry EM; Wang J; Wu T; Davis T; Levine MM
    Vaccine; 2006 May; 24(18):3727-34. PubMed ID: 16169130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.
    Barnoy S; Baqar S; Kaminski RW; Collins T; Nemelka K; Hale TL; Ranallo RT; Venkatesan MM
    Vaccine; 2011 Aug; 29(37):6371-8. PubMed ID: 21596086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of prophylactic recombinant HPV58-attenuated Shigella live vector vaccine and evaluation of its protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model.
    Li W; Liu H; Yang X; Zheng J; Wang Y; Si L
    Acta Biochim Biophys Sin (Shanghai); 2009 Feb; 41(2):137-45. PubMed ID: 19204831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Live Shigella flexneri 2a and Shigella sonnei I vaccine candidate strains with two attenuating markers. I. Construction of vaccine candidate strains with retained invasiveness but reduced intracellular multiplication.
    Linde K; Dentchev V; Bondarenko V; Marinova S; Randhagen B; Bratoyeva M; Tsvetanov Y; Romanova Y
    Vaccine; 1990 Feb; 8(1):25-9. PubMed ID: 2180230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stable expression of Shigella sonnei form I O-polysaccharide genes recombineered into the chromosome of live Salmonella oral vaccine vector Ty21a.
    Dharmasena MN; Hanisch BW; Wai TT; Kopecko DJ
    Int J Med Microbiol; 2013 Apr; 303(3):105-13. PubMed ID: 23474241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine.
    Noriega FR; Losonsky G; Lauderbaugh C; Liao FM; Wang JY; Levine MM
    Infect Immun; 1996 Aug; 64(8):3055-61. PubMed ID: 8757833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers.
    Orr N; Katz DE; Atsmon J; Radu P; Yavzori M; Halperin T; Sela T; Kayouf R; Klein Z; Ambar R; Cohen D; Wolf MK; Venkatesan MM; Hale TL
    Infect Immun; 2005 Dec; 73(12):8027-32. PubMed ID: 16299296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.
    Ranallo RT; Thakkar S; Chen Q; Venkatesan MM
    Vaccine; 2007 Mar; 25(12):2269-78. PubMed ID: 17229494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains.
    Hartman AB; Powell CJ; Schultz CL; Oaks EV; Eckels KH
    Infect Immun; 1991 Nov; 59(11):4075-83. PubMed ID: 1937767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and characterization of virG (icsA)-deleted Escherichia coli K12-Shigella flexneri hybrid vaccine strains.
    Alexander WA; Hartman AB; Oaks EV; Venkatesan MM
    Vaccine; 1996 Aug; 14(11):1053-61. PubMed ID: 8879102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion of HPV L1 into Shigella surface IcsA: a new approach in developing live attenuated Shigella-HPV vaccine.
    Xu D; Wang D; Yang X; Cao M; Yu J; Wang Y
    Antiviral Res; 2014 Feb; 102():61-9. PubMed ID: 24333518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Construction and characterization of a live attenuated Shigella flexneri 2a vaccine strain, sf301 Delta virG and dsbA33G].
    Yang XF; Zhou L; Zheng J; Si LS; Wang YL
    Wei Sheng Wu Xue Bao; 2005 Oct; 45(5):748-52. PubMed ID: 16342769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine.
    Noriega FR; Wang JY; Losonsky G; Maneval DR; Hone DM; Levine MM
    Infect Immun; 1994 Nov; 62(11):5168-72. PubMed ID: 7927802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Multivalent Adhesion Molecule SSO1327 plays a key role in Shigella sonnei pathogenesis.
    Mahmoud RY; Stones DH; Li W; Emara M; El-Domany RA; Wang D; Wang Y; Krachler AM; Yu J
    Mol Microbiol; 2016 Feb; 99(4):658-73. PubMed ID: 26481305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.
    McKenzie R; Walker RI; Nabors GS; Van De Verg LL; Carpenter C; Gomes G; Forbes E; Tian JH; Yang HH; Pace JL; Jackson WJ; Bourgeois AL
    Vaccine; 2006 May; 24(18):3735-45. PubMed ID: 16095766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV; Turbyfill KR
    Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.